TORONTO, ON / August 30, 2021 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to introduce its newest subsidiary, AI Rx Inc. (“AIRX”). AIRX has been established by AIML to hold the exclusive North American commercial usage rights (USA, Canada, Mexico) to Tech2Health’s complete portfolio of digital mental wellness and health-tech products and platform services, patents, technologies, brands and trademarks.
In accordance with the terms of the binding Letter of Intent between AIML and Tech2Health (as announced by AIML on June 28, 2021), AIRX is co-owned on a 70:30 basis between AIML and Tech2Health.
Tech2Health is a Paris, France based digital healthcare innovator with a portfolio of wellness and health-tech products and services designed to improve an individual’s mental well-being by utilizing a unique blend of proprietary digital assets, remote live counselling, and a physical wellness center. Tech2Health has developed a clinically supported and evidence-based methodology consisting of psychotherapies and non-medicinal interventions that apply body and mind healing techniques, delivered via a secure digital platform. In addition to its commercial mental wellness portfolio, Tech2Health is continuously innovating and expanding on its offering as evidenced by the development of its pre-commercial, remote patient monitoring platform.